Arrowhead Pharmaceuticals... (ARWR)
| Bid | 16.1 |
| Market Cap | 2.33B |
| Revenue (ttm) | 545.21M |
| Net Income (ttm) | -146.55M |
| EPS (ttm) | -1.24 |
| PE Ratio (ttm) | -13.63 |
| Forward PE | -4.66 |
| Analyst | Buy |
| Ask | 17 |
| Volume | 1,206,926 |
| Avg. Volume (20D) | 1,831,711 |
| Open | 16.12 |
| Previous Close | 16.09 |
| Day's Range | 16.02 - 16.97 |
| 52-Week Range | 9.57 - 30.41 |
| Beta | 0.95 |
About ARWR
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for ARWR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
Arrowhead Pharmaceuticals to Participate in June 2025 Investor ConferencesPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: Jefferies Glo...
1 month ago · seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call TranscriptArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations for Arrowhead Chris...
1 month ago · businesswire.com
Arrowhead Pharmaceuticals to Participate in May 2025 Investor ConferencesPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securiti...
2 months ago · businesswire.com
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter ResultsPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss ...
2 months ago · businesswire.com
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial OfficerPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will reti...
